|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0086960,
umls-concept:C0146224,
umls-concept:C0282460,
umls-concept:C1140680,
umls-concept:C1513884,
umls-concept:C1521808,
umls-concept:C1522326,
umls-concept:C1554217,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1998-7-1
|
|
pubmed:abstractText |
As topotecan is S-phase-specific, its efficacy is likely schedule-dependent. Therefore, a randomized study using a "pick the winner" design was undertaken to compare two schedules in patients with recurrent ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2233-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9626225-Adolescent,
pubmed-meshheading:9626225-Adult,
pubmed-meshheading:9626225-Aged,
pubmed-meshheading:9626225-Drug Administration Schedule,
pubmed-meshheading:9626225-Female,
pubmed-meshheading:9626225-Humans,
pubmed-meshheading:9626225-Infusions, Intravenous,
pubmed-meshheading:9626225-Injections, Intravenous,
pubmed-meshheading:9626225-Middle Aged,
pubmed-meshheading:9626225-Ovarian Neoplasms,
pubmed-meshheading:9626225-Topotecan,
pubmed-meshheading:9626225-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.
|
|
pubmed:affiliation |
National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Canada. phoskins@bccancer.bc.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
